References
Fleischhacker WW, Lemmens P, van Baelen B (2001) A qualitative assessment of the neurological safety of antipsychotic drugs; an analysis of a risperidone database. Pharmacopsychiatry 34:104–110
Geddes J, Freemantle N, Harrison P, Bebbington P (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321:1371–1376
Gerlach J (2000) Atypical antipsychotics; an inspiring but confusing concept. Psychopharmacology 148:1–2
Kurz M, Hummer M, Oberbauer H, Fleischhacker WW (1995) Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 188:52–56
McEvoy JP, Hogarty GE, Steingard S (1991) Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48:739–745
Meltzer HY (2000) An atypical compound by any other name is still atypical. Psychopharmacology 148:16–19
Nyberg S, Farde S (2000) Non-equipotent doses explain differences among antipsychotics – implications of PET studies. Psychopharmacology 148:22–23
Remington G, Kapur S (2000) Atypical antipsychotics: are some more atypical than others? Psychopharmacology 148:3–5
Schmutz J, Hunziker F, Stille G, Lauener H (1967) Constitution chimique et action pharmacologique d’un nouveau groupe de neuroleptiques tricycliques. Bull Chim Ther 424
Stille G, Hippius H (1971) Kritische Stellungnahme zum Begriff der Neuroleptika. Pharmakopsychiatr Neuropharmakol 4:182–191
World Psychiatric Association (2002) The usefulness and use of second generation antipsychotic medications. Curr Opin Psychiatry (in press)
Zimbroff DL, Kane JM, Tamminga CA, Daniel DG, Mack RJ, Wozniak PJ, Sebree TB, Wallin BA, Kashkin KB (1997) Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Am J Psychiatry 154:782–791
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fleischhacker, W.W. Second generation antipsychotics. Psychopharmacology 162, 90–91 (2002). https://doi.org/10.1007/s00213-002-1064-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-002-1064-8